How a neuroscientist solved the mystery of his own long COVID

Yeah, it’s the difference between research and treatment too I think.
Most of us have access to and interactions with health services, which are really treatment services. Investigations performed are just to find which predefined path we are put on, not to understand something.
If there isn’t a predefined path then you’re pretty much out of luck.

The mention of CIDP is interesting, and something I came across only recently in the context of others who had significant reactions to the covid vaccines.
 
You Can Know Things: 'How a neuroscientist solved the mystery of his own long COVID' (blog)

Jan 07, 2025

(Bolding added by me)
When Jeff Yau started having strange symptoms after his COVID-19 infection – numbness, tingling, and shaking – he experienced what thousands of others with long COVID have found: answers were hard to find, and treatments weren’t working.

But Dr. Jeff Yau was in a unique position: he’s a neuroscientist who runs a lab studying how nerves allow us to sense and perceive the world.

Back at the doctor, testing revealed changes in Jeff’s nerve and muscle function that hadn’t been there months ago. A spinal tap, where fluid was extracted from Jeff’s spine, was the first step to unlocking the mystery of his symptoms: he had an autoimmune disorder called chronic inflammatory demyelinating polyneuropathy (CIDP).
But IVIG wasn’t working, and his symptoms worsened.
In the laboratory, Jeff looked under the microscope at rat nerve tissue that had been treated with his antibodies. Bright colors indicated where his antibodies were attacking the nerve.
More tests revealed the identity of the antibody causing Jeff’s symptoms: an antibody that binds to neurofascin 155, which is a protein that connects the myelin insulation to the nerve.
Pieces of the puzzle began to fall into place: IVIG, the treatment Jeff was receiving, does not work for patients with the neurofascin 155 variant of CIDP. This is because neurofascin 155 antibodies are different from other antibodies: they can bind to myelin without using the resources that IVIG targets.

Jeff brought this information to his doctors. They decided to try plasma exchange treatment instead, which filters the blood and tends to be effective against the neurofascin 155 variant of CIDP. But despite undergoing plasma exchange every two weeks, Jeff’s symptoms kept getting worse.
The measurements showed that Jeff’s neurofascin 155 antibody levels were successfully reduced the day after plasma exchange, but by the time Jeff received his next round of treatment, the levels went back up again. Plasma exchange was not reducing Jeff’s antibody levels fast enough to make a difference in his symptoms.
He started receiving rituximab, a drug that kills the cells that produce antibodies.
“I’m improving a lot now,” Jeff says, “but I don’t feel like I’m anywhere close to being back to baseline or whatever my new baseline will be.”
 
Last edited:
So he developed CIDP due to a Covid infection?
All he knows is the timing matches up, but he can't be sure it's the cause.
Correlation does not equal causation, and although Jeff's symptoms showed up shortly after COVID-19 infection, it's impossible to say with certainty what caused Jeff's illness.
'The hard thing, just like with my own diagnosis of CIDP, is that I can’t say this was definitively due to COVID infection, even though the timing is very much consistent. My view of COVID is let me just not get it again.'
 
https://www.youcanknowthings.com/how-one-neuroscientist-solved-the-mystery-of-his-own-long-covid-2/

Interesting article, sadly few have access to this level of testing

Ritixumab being used
Interesting

and odd to read just after I’ve read the thread on Suzanne o’Sullivan, who was also apparently a neurologist, but also a storytelling author, where the latest is her giving her options on long covid and psychosomaticism and then goes on to start listing many other specialty clinics she says 30% of patients attending are psychosomatic like respiratory and gynaecology
 
Back
Top Bottom